Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
protease inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AE12
|
| gptkbp:CASNumber |
394730-60-0
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
direct-acting antiviral
|
| gptkbp:eliminationHalfLife |
3.4 hours
|
| gptkbp:hasMolecularFormula |
C27H45N5O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
boceprevir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Victrelis
|
| gptkbp:metabolism |
liver
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue dysgeusia |
| gptkbp:target |
gptkb:NS3/4A_serine_protease
|
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:withdrawn |
2015
yes |
| gptkbp:bfsParent |
gptkb:Victrelis
|
| gptkbp:bfsLayer |
5
|